Division Highlights - Pulmonology & Cystic Fibrosis
The Division of Pediatric Pulmonology provides family-centered care for children with respiratory disorders, including asthma, cystic fibrosis, and chronic lung disease.
Research efforts aim to improve the health of children with lung diseases.
- Donald Sanders, MD, joined the division.
- Christopher Green, MD, was an instructor at bronchoscopy courses in Cincinnati, Ohio, and Madrid, Spain.
- Theresa Guilbert, MD, designed a CME-accredited teleconference lecture series, “The Identification and Management of RSV-related Disease Burden”.
- Michael Rock, MD, received a Clinical Research Facilitation Award from Cystic Fibrosis Foundation Therapeutics, Inc. He also participated in clinical trials studying inhaled hypertonic saline in infants with cystic fibrosis and enzyme efficacy in children with cystic fibrosis.
- Mary Schroth, MD, presented “Respiratory Care of Neuromuscular Weakness” and “Breathing Basics in SMA” to the Families of SMA Argentina in Buenos Aires.
Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ, Lemanske RF Jr, Moss M, Szefler SJ, Krawiec M, Boehmer S, Mauger D, Taussig LM, Martinez FD; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol. 2009 May;123(5):1077-82, 1082.e1-5. Epub 2009 Feb 23.
Borowitz D, Parad R, Sharp JK, Sabadosa K, Robinson KA, Rock M, Farrell P, Sontag M, Rosenfeld M, Davis S, Marshall B, Accuroso F and other contributors. Cystic fibrosis foundation practice guidelines for the management of infants with CFTR-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 155:S106-S116, 2009.
Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 155:S73-S93, 2009.
Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M Jr, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 8:153-73, 2009.
Cystic Fibrosis Foundation, Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009 Dec;155(6 Suppl):S106-16.
Danov Z, Guilbert T. Regular use of inhaled corticosteroids controls symptoms of mild persistent asthma, but with growth effect. J Pediatr. 2009 Jan;154(1):150.
Farrell PM, Collins J, Broderick LS, Rock MJ, Li Z, Kosorok MR, Laxova A, Gershan WM, Brody AS. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology. 2009 Aug;252(2):534-43.
Kloosterboer M, Hoffman G, Rock MJ, Gershan W, Laxova A, Li Z, Farrell, PM. Clarification of laboratory variables influencing CF newborn screening with initial analysis of immunoreactive trypsinogen. Pediatr. 123(9): e338-346, 2009.
Lai HC, Shoff SM, Farrell PM and the Wisconsin CF Neonatal Screening Group. Recovery of birth weight z-score within two years of diagnosis is positively associated with pulmonary status at age six years in children with cystic fibrosis. Pediatr. 123: 714-722. 2009.
Larsen GL, Morgan W, Heldt GP, Mauger DT, Boehmer SJ, Chinchilli VM, Lemanske RF Jr, Martinez F, Strunk RC, Szefler SJ, Zeiger RS, Taussig LM, Bacharier LB, Guilbert TW, Radford S, Sorkness CA; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma. J Allergy Clin Immunol. 2009 Apr;123(4):861-7.e1. Epub 2008 Dec 12.
Paul IM, Camera L, Zeiger RS, Guilbert TW, Bacharier LB, Taussig LM, Morgan WJ, Covar RA, Krawiec M, Bloomberg GR, Mauger DT; Childhood Asthma Research and Education (CARE) Network. Relationship between infant weight gain and later asthma. Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 1):82-9. Epub 2009 Aug 27.
Rao AR, Laxova A, Farrell PM, and Barbieri JT. Porteomic identification of OprL as a seromarker for the initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis. J Clinical Microbiology. 47:2483-8, 2009.
Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics. 2009 May;123 Suppl 4:S245-9. Review.
Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM, Elsheikh B, Simard LR. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4(5):e5268. Epub 2009 May 14.
Tippets B, Guilbert TW. Asthma: Making the Diagnosis and Assessing Severity. Consultant for Pediatricians, May 2009.
Tippets B, Guilbert TW. Asthma: Tips for Achieving and Maintaining Control. Consultant for Pediatricians, June 2009.
Varness T, Seffrood EE, Connor EL, Rock MJ, Allen DB. Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis. Int J Pediatr Endocrinol. 2009;2009:826895. Epub 2010 Jan 24.
|Principal Investigator||Funding Agency||Title|
|Farrell, Philip||DHHS, PHS, National Institutes of Health||Pulmonary Benefits of Cystic Fibrosis Neonatal Screening|
|Farrell, Philip||Cystic Fibrosis Foundation||Pulmonary Benefits of CF Neonatal Screening|
|Guilbert, Theresa||UW - ICTR||Innate Immune Response to RSV in Early Life (IREL Study)|
|Rock, Michael||Wisconsin Dept of Health Services||Congenital Disorders Program|
|Rock, Michael||Altus Pharmaceuticals||ALTU-135 In Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|
|Rock, Michael||Inspire Pharmaceuticals, Inc||Denufosoltetrasodium (Ins37217) - Clinical Trial|
|Rock, Michael||Children's Hospital Seattle||EPIC Study: Longitudinal Assessment In Children with CF|
|Rock, Michael||Children's Hospital Seattle||Antimicrobial Therapy For Pseudomonas Aeruginosa Airway Infection In CF|
|Rock, Michael||Johns Hopkins University||Genetic Modifiers of Cystic Fibrosis|
|Rock, Michael||Cystic Fibrosis Foundation||Cystic Fibrosis Clinical Research Facilitation Award|
|Rock, Michael||Cystic Fibrosis Foundation||CFF Fellowship|
|Rock, Michael||Cystic Fibrosis Foundation||CF Center|
|Rock, Michael||Cystic Fibrosis Foundation||CFF Fellowship|
|Rock, Michael||Cystic Fibrosis Foundation Therapeutics||Cystic Fibrosis Therapeutics Development Network Centers|
|Schroth, Mary||DHHS, PHS, Health Resources and Services||Pediatric Pulmonary Center Training Grant|
|Schroth, Mary||Spinal Muscular Atrophy Foundation||SMA Biomarker Pilot Study|